Suppr超能文献

丁苯酞联合艾地苯醌对血管性痴呆患者炎性细胞因子及血管内皮功能的影响

Effects of Butyphthalide Combined with Idebenone on Inflammatory Cytokines and Vascular Endothelial Functions of Patients with Vascular Dementia.

作者信息

Qi Fan-Xing, Hu Ying, Kang Li-Juan, Li Pan, Gao Tian-Chu, Zhang Xin

机构信息

Department of Neurology, Baoding First Central Hospital, Baoding, China.

Department of Cardiology, Baoding First Central Hospital, Baoding, China.

出版信息

J Coll Physicians Surg Pak. 2020 Jan;30(1):23-27. doi: 10.29271/jcpsp.2020.01.23.

Abstract

OBJECTIVE

To determinate the clinical effect of butyphthalide combined with idebenone in the treatment of vascular dementia (VD) and the influence on inflammatory cytokines and vascular endothelial functions.

STUDY DESIGN

Clinical comparative study.

PLACE AND DURATION OF STUDY

Department of Neurology, Baoding First Central Hospital, from June 2017 to June 2018.

METHODOLOGY

Eighty-eight VD patients were divided into observation group (44 cases) and control group (44 cases) at random. Idebenone was given to the control group, and butyphthalide combined with idebenone was given to the observation group for 12 weeks. C-reactive protein (CRP), tumor necrosis factor α (TNF-α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) were detected before and after the treatment to evaluate the level of serum inflammatory factors. Peripheral blood endothelial microparticles (EMPs), endothelin (ET-1), and vascular endothelial growth factor (VEGF) were detected to evaluate vascular endothelial functions. Mini-mental state examination (MMSE), clinical dementia scale (CDR), and ability of daily life (ADL), were used to evaluate cognitive function, dementia degree, and self-care ability in daily life. The occurrences of adverse reactions were recorded.

RESULTS

Before the treatment, the comparison differences in the indexes of both groups had no statistical significance (p>0.05). After the treatment, the scores of CD62E+, VEGF, and MMSE of observation group rose obviously, compared with those before the treatment, and were significantly higher than those of control group (p <0.05). After the treatment, the scores of IL-6, CRP, TNF-α, IL-1β, CD31+, CDl44+, ET-1, CDR and ADL of observation group significantly lowered, compared with those before the treatment, and were significantly lower than those of control group (p <0.05). The differences in the adverse reactions of both groups had no statistical significance (p >0.05).

CONCLUSION

Butyphthalide combined with idebenone can effectively reduce serum inflammatory factor level of VD patients, regulate vascular endothelial functions, relieve dementia degree, and improve cognitive function and daily activity ability.

摘要

目的

探讨丁苯酞联合艾地苯醌治疗血管性痴呆(VD)的临床疗效及对炎性细胞因子和血管内皮功能的影响。

研究设计

临床对照研究。

研究地点和时间

2017年6月至2018年6月在保定市第一中心医院神经内科。

方法

将88例VD患者随机分为观察组(44例)和对照组(44例)。对照组给予艾地苯醌,观察组给予丁苯酞联合艾地苯醌治疗12周。治疗前后检测C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)、白细胞介素-6(IL-6)和白细胞介素-1β(IL-1β),以评估血清炎性因子水平。检测外周血内皮微粒(EMPs)、内皮素(ET-1)和血管内皮生长因子(VEGF),以评估血管内皮功能。采用简易精神状态检查表(MMSE)、临床痴呆评定量表(CDR)和日常生活能力量表(ADL)评估认知功能、痴呆程度和日常生活自理能力。记录不良反应的发生情况。

结果

治疗前,两组各项指标比较差异无统计学意义(p>0.05)。治疗后,观察组CD62E+、VEGF和MMSE评分较治疗前明显升高,且显著高于对照组(p<0.05)。治疗后,观察组IL-6、CRP、TNF-α、IL-1β、CD31+、CDl44+、ET-1、CDR和ADL评分较治疗前显著降低,且显著低于对照组(p<(0.05)。两组不良反应差异无统计学意义(p>0.05)。

结论

丁苯酞联合艾地苯醌可有效降低VD患者血清炎性因子水平,调节血管内皮功能,减轻痴呆程度,改善认知功能和日常生活活动能力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验